                         SEQUENCE LISTING

<110>  Sarepta Therapeutics, Inc.
       
 
<120>  PEPTIDE OLIGONUCLEOTIDE CONJUGATES

<130>  581438: SPT-001PC

<150>	62/163,960
<151>	2015-05-19

<150>	62/337,536
<151>	2016-05-17

<160>  15    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  1

Cys Arg Arg Arg Cys Arg Gly 
1               5           


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  2

Cys Arg Arg Arg Cys Arg Arg Gly 
1               5               


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  3

Cys Arg Arg Arg Cys Arg Arg Arg Gly 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  4

Cys Arg Arg Arg Arg Arg Arg Cys Gly 
1               5                   


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  5

Cys Arg Arg Arg Arg Arg Cys Gly 
1               5               


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  6

Cys Arg Arg Arg Arg Cys Gly 
1               5           


<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  7

Cys Arg Arg Arg Cys Gly 
1               5       


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide; see specification for cysteine modifications


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  8

Cys Arg Arg Cys Gly 
1               5   


<210>  9
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  phosphorodiamidate-linked morpholino oligomer


<220>
<221>  misc_feature
<222>  (1)..(18)
<223>  phosphorodiamidate-linked morpholino residues

<400>  9
gctattacct taacccag                                                     18


<210>  10
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Dystrophin outer forward primer

<400>  10
caatgtttct ggatgcagac tttgtgg                                           27


<210>  11
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Dystrophin outer reverse primer

<400>  11
gttcagcttc actctttatc ttctgcc                                           27


<210>  12
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Dystrophin inner forward primer

<400>  12
cacatctttg atggtgtgag g                                                 21


<210>  13
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Dystrophin inner reverse primer

<400>  13
caacttcagc catccatttc tg                                                22


<210>  14
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  phosphorodiamidate-linked morpholino oligomer


<220>
<221>  misc_feature
<222>  (1)..(25)
<223>  phosphorodiamidate-linked morpholino residues

<400>  14
ggccaaacct cggcttacct gaaat                                             25


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<400>  15

Arg Arg Arg Arg Arg Arg Gly 
1               5           


